In a landmark move for English cricket, stakes in each of the eight teams in The Hundred are being sold. It has been a ...

The company has a lower Return on Equity (ROE) of 8.17%, which is 4.87% below the industry average. This indicates potential ...

The improving environment for deals is encouraging some smaller firms to start hunting much larger prey.Most Read from ...

Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...